Jones et al. published in a recent issue of the European Journal of Cancer a seminal study describing the long-term efficacy results of new generation tyrosine
kinase inhibitor, avapritinib, in a rare subtype of gastrointestinal stromal tumor
(GIST), namely PDGFRα D842V-mutant GIST which is primary resistant to imatinib [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial.Eur J Cancer. 2021 Mar; 145: 132-142
- Next questions for the medical treatment of gastrointestinal stromal tumor.Curr Opin Oncol. 2022 Jul 1; 34: 348-353
- BRAF mutation status in gastrointestinal stromal tumors.Am J Clin Pathol. 2010 Jan; 133: 141-148
- Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients.Ann Oncol. 2021 Dec; 32: 1642-1645
- BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.Oncotarget. 2013 Feb; 4: 310-315
- Clinical development of BRAF plus MEK inhibitor combinations.Trends Cancer. 2020 Sep; 6: 797-810
- BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.Pigment Cell Melanoma Res. 2018 May; 31: 432-436
- Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.Org Biomol Chem. 2017 Apr 18; 15: 3455-3465
Article info
Publication history
Published online: December 02, 2022
Accepted:
October 20,
2022
Received in revised form:
October 13,
2022
Received:
August 18,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialEuropean Journal of CancerVol. 145
- PreviewPDGFRA D842V mutations occur in 5–10% of gastrointestinal stromal tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive against this mutation. Consequently, patients have a poor prognosis. We present an updated analysis of avapritinib efficacy and long-term safety in this patient population.
- Full-Text
- Preview
